Editorial
A novel miR-205-mediated ERRFI1/EGFR regulatory pathway in MET-addicted cancer cells: emerging biomarkers for secondary resistance
Abstract
In the last two decades, many efforts have been made towards the development of innovative and targeted therapeutic approaches for cancer treatment. Nonetheless, in contrast to the several hallmarks achieved in recent years, drug resistance to cancer therapies has arisen as the real challenge.
